Quest Diagnostics (DGX) recently announced a collaboration with the leading health and fitness platform, Fitbit, to study the potential of wearable devices to improve metabolic health. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair behavioral and biometric data from Fitbit devices with health insights from Quest Diagnostics' laboratory tests to explore ways to combine and analyze data for the enhanced assessment and management of metabolic health and aid in disease prevention.The latest ...

Blood tests for dozens of types of cancer have been invented. These tests, known as liquid biopsies, could save tens of millions of lives. That’s because there’s currently no good screening procedures for many types of cancers, such as pancreatic cancer and lung cancer. And by the time the tumors cause symptoms, it’s usually too late to save the patients’ lives. Also noteworthy is that these diagnostics, or multi-cancer early detection tests (MCEDs), can save hospitals and health insurers a great deal of mo ...

SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2023 financial results on Thursday, February 1, 2024, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.    The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0 ...

Quest Diagnostics (DGX) recently announced a collaboration with Ultima Genomics, the developer of the revolutionary new ultra-high throughput sequencing architecture. Through the collaboration, the companies aim to improve patient access, affordability and outcomes by expanding the use of highly accurate, cost-efficient and high-volume whole genome sequencing in fast-growth areas, such as solid-tumor minimal residual disease (MRD) testing.The latest development will significantly fortify Quest Diagnostics’ ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and traditional valuation metrics to find s ...

Quest Diagnostics Inc. (DGX) recently acquired select assets of Steward Health Care System's outreach laboratory services business, which provided services to physicians and patients in Pennsylvania and Ohio. The transaction's financial specifics were kept under wraps.The agreement gives patients and doctors more access to cutting-edge, excellent-quality diagnostic information services.The latest development is likely to broaden Quest Diagnostics' laboratory services offering.More on AgreementQuest Diagnost ...

FREMONT, Calif & SECAUCUS, N.J.--(BUSINESS WIRE)--Ultima Genomics, a developer of a revolutionary new ultra-high throughput sequencing architecture, and Quest Diagnostics (NYSE: DGX), the nation’s leading provider of diagnostic information services, today announced a collaboration involving Ultima’s next generation sequencing (NGS) technology in oncology and other clinical areas. The collaboration aims to improve patient access, affordability and outcomes by broadening the use of highly accurate, cost-ef ...

BALTIMORE, Jan. 8, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology's personalized MRD technology (Haystack MRD™) to analyze therapeutic response and provide molecular insights for AFT's interventional, randomized phase II clinical trial (AFT-57) in patients with unresectable stage III non-small cell lung cancer (NSCLC). The AFT-57 clinical study is supported by G ...

Quest Diagnostics Inc. (DGX) is likely to grow in the coming quarters, backed by strength in the legacy base business. The company is gaining from collaborations with health plans, hospitals and physicians amid a broad return to care. However, a high debt level on the balance sheet and intense competition also raise concerns.In the past year, this Zacks Rank #3 (Hold) stock has declined 8.9% against the industry’s 9% growth and a 24.5% rise of the S&P 500 composite.The renowned provider of diagnostic inform ...

SECAUCUS, N.J., Dec. 21, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that Jim Davis, Chairman, CEO and President, and Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance, and the latest market developments and trends during a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024, at 6:45 p.m. ...